

BASED IN LA ROCHELLE, VALBIOTIS WILL EXPAND AND OPEN A NEW LOCATION IN CLERMONT-FERRAND ON FEBRUARY 1ST

VALBIOTIS, with a capital of €189,400, was founded in La Rochelle in 2014.

Its proprietary R&D platform develops preventative solutions for serious public health issues stemming from the chronic **metabolic disorders** that have come to define our century.

These solutions, both nutritional and medicinal, are indicated for specific stages of disorders such as type 2 diabetes (*3.4 million people in France, and 5.4 million pre-diabetics*), obesity (*10.3 million*), dyslipidemia (*13.6 million*), and NASH (Nonalcoholic Steatohepatitis).

Since its founding, VALBIOTIS has received approximately 3 million euros in financial support, both from private investors as well as innovation-funding initiatives.

VALBIOTIS was also awarded the **French Ministry of Research I-LAB prize for innovation in 2015** in the "Creation-Development" category.

The company's project received about 50 press mentions, and in April 2015 it was featured in a major issue called "*les 100 starts up dans lesquelles investir*" [*the top 100 start-ups in which to invest*] published in **Challenges** magazine.

The deeply-rooted scientific, nutritional activities in the Auvergne-Rhône Alpes region, as well as the industrial activity in the economic center of Clermont-Ferrand, will give VALBIOTIS a strong advantage as it prepares to open a second location in the area on February 1st.

VALBIOTIS has already invested approximately **1 million euros in the region**, and already has several regional scientific and financial partners, including Blaise Pascal University and Sofimac Partners, one of its existing investors based in Clermont-Ferrand.

VALBIOTIS will be attending the 2016 Convention of the French Diabetes Association taking place at the Cité Centre de Congrès in Lyon from March 22 to 25.



Valbiotis Polytech
2 avenue Blaise Pascal 63178

For more information

www.valbiotis.fr